Cannabis Investment Report

Cannabis Investment Report | December 2017 Representative Dosage Amounts Desired Effect or Ailment Dosage “High” 10 mg THC Anxiety, depression, spasms 25 mg CBD Cancer 25 mg CBD Chronic pain 2.5-20 mg THC Epileptic seizures 200-300 mg CBD Glaucoma 20-40 mg CBD Increased appetite 2.5 mg THC Multiple sclerosis 2.5-120 mg THC 40-1,280 mg CBD 40-160 mg CBD Schizophrenia Sleep disorders Neither the potential medicinal benefits and therapeutic Dosage Ratio (THC:CBD) 10:1 to 100:1 1:10 1:1 10:1 1:5 1:2 to 1:4 5:1 1:1 1:4 to 1:128 1:4 to 1:16 applications of cannabis consumption nor the negative side effects of cannabis use have been thoroughly researched by medical science. Short- term negative side effects are believed by some to include sensory distortion, panic, anxiety, poor coor- dination of movement, reduced reaction time, lethargy or drowsiness, depression and elevated heart rate. Longer-term effects may include suppression of the immune system, growth disorders, destruc- tion of lung fibers, brain lesions, reduced sexual capacity, difficulties with concentration, reduced abil- ity to learn and retain information, and personality and moo about whether cannabis consumption may lead to the abuse “gateway drug” debate). 30 d changes. There is also an ongoing debate of more harmful substances (the so-called © 2017 Ackrell Capital, LLC | Member FINRA/SIPC HOUSE_OVERSIGHT_024666